SynthesisInternational journal of molecular sciences2017
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility.
Synthesis in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression.Molecular oncology · 2025Article
- Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.Journal of nanobiotechnology · 2024Review
- A Prospective Tumour Marker for Breast Cancer: YWHAB and Its Role in Promoting Oncogenic Phenotypes.Breast cancer (Dove Medical Press) · 2024Article
- Plasma hPGBMC cancer · 2023Article
- Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications.Frontiers in molecular biosciences · 2022Review
- Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late.Diagnostics (Basel, Switzerland) · 2021Article
- Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.International journal of molecular sciences · 2021Review
- Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.Bioscience reports · 2020Article
- The Hypoxic Response Expression as a Survival Biomarkers in Treatment-Naive Advanced Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- CAncer bioMarker Prediction Pipeline (CAMPP)-A standardized framework for the analysis of quantitative biological data.PLoS computational biology · 2020Article
- Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion.International journal of molecular sciences · 2019Review
- Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives.International journal of molecular sciences · 2019Review
- Advances in liquid biopsy approaches for early detection and monitoring of cancer.Genome medicine · 2018Article
- Evidence on the cost of breast cancer drugs is required for rational decision making.Ecancermedicalscience · 2018Article
- Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.Breast cancer research : BCR · 2017Article
- Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.Biomarker research · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reviews on circulating biomarkers in breast cancer usually focus on one single biomarker or a selective group of biomarkers. An overview summarizing the discovery and evaluation of all blood-based biomarkers in metastatic breast cancer is lacking. This systematic review aims to identify the available evidence of known blood-based biomarkers in metastatic breast cancer, regarding their clinical utility and state-of-the-art position in the validation process. The initial search yielded 1078 original studies, of which 420 were assessed for eligibility. A total of 320 studies were included in the final synthesis. A Development, Evaluation and Application Chart (DEAC) of all biomarkers was developed. Most studies focus on identifying new biomarkers and search for relations between these biomarkers and traditional molecular characteristics. Biomarkers are usually investigated in only one study (68.8%). Only 9.8% of all biomarkers was investigated in more than five studies. Circulating tumor cells, gene expression within tumor cells and the concentration of secreted proteins are the most frequently investigated biomarkers in liquid biopsies. However, there is a lack of studies focusing on identifying the clinical utility of these biomarkers, by which the additional value still seems to be limited according to the investigated evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.